-+ 0.00%
-+ 0.00%
-+ 0.00%

Medexus FY27 Q1 adjusted EBITDA climbs 38.2% to US$4.7 million; revenue rises 16.3% to US$28.6 million

PUBT·08/10/2026 21:32:16
Listen to the news
Medexus FY27 Q1 adjusted EBITDA climbs 38.2% to US$4.7 million; revenue rises 16.3% to US$28.6 million
  • Medexus posted net revenue of USD 28.6 million, up 16.3% year over year.
  • Operating income climbed to USD 2.1 million, up 133.3% year over year, on increasing operating leverage from GRAFAPEX.
  • IFRS net income held at USD 544,000, while adjusted EBITDA rose to USD 4.68 million from USD 3.44 million a year earlier.
  • GRAFAPEX product-level net revenue reached USD 4.9 million, exceeding USD 3.2 million of related personnel and infrastructure investments.
  • Management reiterated fiscal 2027 GRAFAPEX product-level net revenue outlook of USD 30 million to USD 32 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medexus Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608101730NEWSFILECNPR____20260810_309074_1) on August 10, 2026, and is solely responsible for the information contained therein.